ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ZTS / earnings
GMAB (70) RPRX (76) ROIV (42) ONC (71) ⌘ Pro Terminal →

Zoetis Inc. (ZTS) Next Earnings Date & Expected ±4.7% Move

$83.18 +4.34% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $83.67

Zoetis Inc. (ZTS) carries a Roarable Rating of C+ (Hold) with 68/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C+ • HOLD / WATCH Cap $32.94B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ZTS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ZTS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Zoetis Inc. (NYSE: ZTS) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 68/100 at a spot price of $83.18 (+4.34% 1D, market cap $32.94B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 15/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 18/20. Across 1015 tracked Health Care issuers, ZTS ranks #89 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ZTS compare to GMAB and RPRX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ZTS carries a Roarable C+ (68/100 RQD), trailing P/E of 12.2x, gross margin of 71.8%, and ROIC of 25.7%. By comparison, GMAB (Genmab A/S ADS) holds a B- grade (70/100 RQD, P/E 32.8x, ROIC 9.9%, cap $35.61B) and RPRX (Royalty Pharma plc (Class A)) posts a B+ grade (76/100 RQD, P/E 49.2x, ROIC 7.0%, cap $38.63B). Among the 5-stock peer group, ZTS leads on earnings multiple (12.2x) while ZTS leads on capital efficiency (25.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ZTS?
▼

Per ZTS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001555280), Zoetis Inc. generated $9.47B in revenue (+2.3% YoY), $2.67B in net income, and $2.28B in free cash flow against $15.49B in total assets and $9.04B in total debt. Key quantitative strengths: Strong cash generator (71.8% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $83.67 (+0.59%)🧬 Cannibal Buyback (-2.92% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 24.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 68/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.8% avg 90D alpha vs SPY • 56.9% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C+
025507510068
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B+ · Rk D+
Cash (17)Whales (11)SEC (15)Macro (7)CEO (18)
Each axis scored 0–20
12M PRICE TARGET CONE+4.5% Base Target
$152 Bull$87 Base$68 Bear
📬 FREE ZTS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ZTS)Realized 20D OHLCV Swing Band: ±4.7%
Deterministic 5-Pillar Attribution (68/100 Composite)
🔍 WHY ZTS SCORES 68/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Insider Conviction & Share Dilution+18/20 pts (26% of score)

SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-2.92% YoY Shares)

▲ #2 Bullish Driver: Cash Engine Quality+17/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 24.1% FCF Margin ($2.28B FCF) & 71.8% Gross Margin

▼ #1 Drag / Risk Factor: Macro Regime Fit7/20 pts (-13 pt drag)

Macro rate sensitivity & RSI-14 (59.6) create a -13 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
60
Grade C$75.29+5.8% Next Q
Q2 (-2Q)
63
Grade C+$79.62-2.3% Next Q
Q3 (-1Q)
65
Grade C+$77.80+6.9% Next Q
Current
68
Grade C+$83.18+1.8% Hist 90D α
Trajectory: C (60) → C+ (68)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ZTS Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 68/100 (C+) score, ZTS faces multiple-compression risk if 12.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.92% YoY Shares) — any gross margin slip below 69.3% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($75.15) or 200D SMA ($92.85) invalidates the momentum regime and cuts Target Base ($86.92) toward Bear Floor ($67.80).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ZTS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ZTS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 68%NO 32%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±4.7% Swing Band

±$3.91 Expected Swing
$79.27 (-4.7%)Spot $83.18$87.09 (+4.7%)
MODEL EARNINGS SETUP GAUGE

ZTS Quantitative Pre-Earnings Setup: 68/100

Trailing EPS: $6.47 • YoY Revenue Growth: 2.3%

Model Bullish Setup (68/100)Model Risk Weight (32/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$9.47B$2.67B$2.28B71.8%
FY 20242024-12-31$9.26B$2.49B$2.30B70.6%
FY 20232023-12-31$8.54B$2.34B$1.97B71.8%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating ZTS & AI Leaders Without Chasing Tops

  • ✓Institutional whale strikes & implied earnings move audit on ZTS
  • ✓How disciplined traders manage risk using pre-published trigger & invalidation levels
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ZTS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -26.18%⚡ TESTING RESISTANCE
2026-11-03O $78.80H $83.18L $78.80C $83.18VOL 4.12M
RES: $83.09SUP: $67.83SMA50: $75.15SMA200: $92.85
$136.4$118.1$99.76$81.42$63.08RES $83.09SUP $67.83$83.182026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ZTS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ZTS Butterfly Map → + Track ZTS →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
2.8%/yr Implied 5Y Growth

vs. +2.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ZTS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ZTS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ZTS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ZTS)

Health Care Rank #89 of 1015 ⚔️ GMAB vs ZTS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ZTS vs. GMAB, RPRX, ROIV, ONC)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Zoetis Inc. (ZTS) ranks #89 by composite RQD confidence (68/100, grade C+) and #54 by equity capitalization ($32.94B). Within this direct 5-issuer industry benchmark cohort, ZTS leads on earnings valuation at 12.2x trailing P/E, while ZTS leads on capital efficiency and profitability with 25.7% ROIC and 71.8% gross margin. RPRX currently holds the highest overall quantitative score in the immediate peer group at 76/100 (B+) compared with ZTS at 68/100 (C+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ZTS ACTIVE
Zoetis Inc.
C+ 68/100 12.2x 71.8% 25.7% +4.34% $32.94B Benchmark Subject
GMAB
Genmab A/S ADS
B- 70/100 32.8x — 9.9% -3.75% $35.61B /gmab-vs-zts →
RPRX
Royalty Pharma plc (Class A)
B+ 76/100 49.2x — 7.0% -0.98% $38.63B /rprx-vs-zts →
ROIV
Roivant Sciences Ltd.
D- 42/100 — — -14.0% -2.76% $26.66B /roiv-vs-zts →
ONC
BeOne Medicines Ltd.
B- 71/100 147.2x 87.5% 10.5% -2.45% $42.11B /onc-vs-zts →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001555280 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Zoetis Inc. (ZTS) reported GAAP revenue of $9.47B (+2.3% vs. FY2024 revenue of $9.26B , and +10.8% cumulative change since FY2023) , GAAP net income of $2.67B, operating cash flow of $2.90B, and free cash flow of $2.28B (-0.7% YoY). On the balance sheet, ZTS closed FY2025 with $15.49B in total assets against $9.04B in total debt (Altman Z-Score: 4.53, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $9.47B $2.67B $2.90B $2.28B $15.49B $9.04B
FY2024 (FY) 2024-12-31 $9.26B $2.49B $2.95B $2.30B $14.24B $5.22B
FY2023 (FY) 2023-12-31 $8.54B $2.34B $2.35B $1.97B $17.91B $4.19B

3. ZTS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ZTS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Zoetis Inc. (NYSE: ZTS) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 68/100 at a spot price of $83.18 (+4.34% 1D, market cap $32.94B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 15/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 18/20. Across 1015 tracked Health Care issuers, ZTS ranks #89 in composite RQD confidence.

How does ZTS compare to GMAB and RPRX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ZTS carries a Roarable C+ (68/100 RQD), trailing P/E of 12.2x, gross margin of 71.8%, and ROIC of 25.7%. By comparison, GMAB (Genmab A/S ADS) holds a B- grade (70/100 RQD, P/E 32.8x, ROIC 9.9%, cap $35.61B) and RPRX (Royalty Pharma plc (Class A)) posts a B+ grade (76/100 RQD, P/E 49.2x, ROIC 7.0%, cap $38.63B). Among the 5-stock peer group, ZTS leads on earnings multiple (12.2x) while ZTS leads on capital efficiency (25.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ZTS?

Per ZTS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001555280), Zoetis Inc. generated $9.47B in revenue (+2.3% YoY), $2.67B in net income, and $2.28B in free cash flow against $15.49B in total assets and $9.04B in total debt. Key quantitative strengths: Strong cash generator (71.8% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ZTS trading relative to its 50-day, 200-day, and 52-week technical levels?

ZTS last traded at $83.18 (+4.34% on volume of 5,418,175 shares), positioning the stock +10.69% above its 50-day simple moving average ($75.15) and -10.41% below its 200-day simple moving average ($92.85). Across its 52-week range of $68.77 to $144.83, ZTS sits at the 18.9% percentile with a 14-day RSI of 59.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±4.7% ($79.27 to $87.09).

Direct Sub-Reports: ZTS RQD Cockpit ZTS 12M Forecast ZTS Earnings & Move ZTS Dividends & DRIP ZTS Insiders & 13F ZTS Whale Options ZTS Profit Sankey ZTS News & Why
ROARABLE RATING BRIEF • RQD 68/100 (C+) ✓ SEC XBRL & RQD VERIFIED

ZTS — Zoetis Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Zoetis Inc. (ZTS) earns a live Roarable RQD composite score of 68/100, corresponding to a C+ letter grade (Roarable Hold) at a spot price of $83.18 (+4.34% 1D, market capitalization $32.94B).

  • Fundamental Cash Engine (17/20): Anchored by return on invested capital (ROIC) of 25.7%, gross margin of 71.8%, operating margin of 34.4%, and free cash flow yield of 7.01%.
  • Whale 13F & Options Flow (11/20) + Insider Conviction (18/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (15/20): Incorporates a 0.99x equity beta, Altman Z-Score of 4.53, Piotroski F-Score of 7/9, and Debt/Equity of 2.65x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Zoetis Inc. Is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The profile does not describe its products, customers, or revenue model. The company generated revenue of $9.47B in FY 2025. Gross margin of 71.8% and operating margin of 34.4% are reported per the market data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Zoetis Inc. (ZTS) reported $9.47B in annual revenue (up from $9.26B in FY2024, +2.3% YoY) and $2.67B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($8.54B revenue, $2.34B net income) through FY2025, ZTS scaled operating cash flow to $2.90B and free cash flow to $2.28B, backed by $15.49B in total assets against $9.04B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C+ • RQD 68/100): Strong cash generator (71.8% gross margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 17/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $68.77 – $144.83 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 12.2x trailing P/E and 10.3x EV/EBITDA against 34.4% operating margins and a 0.99x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies: — Sector correlations: — Second-order bottlenecks: — Investors should treat the absence of mapped links as a gap in the analysis rather than evidence that no ripple effects exist.

  • Key Question #1: Can ZTS sustain or expand its 34.4% operating margin and 25.7% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $9.47B and free cash flow of $2.28B, how will capital allocation balance growth reinvestment against $9.04B in total debt?
  • Key Question #3: How sensitive is ZTS's 11.3x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.99x)?

ZTS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Zoetis Inc. (ZTS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ZTS Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ZTS Bull vs. Bear Conversation Board — What's Your Call at $83.18?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ZTS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ZTS:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $98.85 (+24.0%)
📌 Pinned Debate

Pillar scores show a 25.7% ROIC and 7.01% FCF yield at a 12.2x trailing P/E, with insider conviction scoring 18/20.

Here is why I am bullish on ZTS here at $79.72: Pillar scores show a 25.7% ROIC and 7.01% FCF yield at a 12.2x trailing P/E, with insider conviction scoring 18/20.. Compare ZTS's 34.4% operating margin and 25.7% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $75.73 are getting bought.

RetailWhale_TX 🐂 BULL

@CreditSpread_Watch Shorting a 11/20 institutional whale-flow stock at $79.72 is dangerous when funds are rotating into Health Care.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $66.96 (-16.0%)
Spot @ $79.72

Leverage has climbed to a 2.65 Debt/Equity ratio while macro regime fit scores only 7/20 at a 0.99 beta.

Careful chasing ZTS at $79.72. Leverage has climbed to a 2.65 Debt/Equity ratio while macro regime fit scores only 7/20 at a 0.99 beta.. Gross margin is 71.8%, but operating margin is 34.4%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $66.96 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%